RPRX

+ Watchlist + Portfolio

Royalty Pharma plc

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $61.73
52-Week Range: $34.08 – $62.10
Market Cap: $35.01B
P/E (TTM): 32.57
EPS (TTM): 1.86
Dividend Yield: 1.52%

Advanced Metrics

Price/Book: 3.95
PEG Ratio: 2.19
Return on Equity: 13.96%
Return on Assets: 5.09%
Gross Margin: 95.82%
Operating Margin: 19.75%
Profit Margin: 32.02%
Current Ratio: 2.80
Debt/Equity: 0.92
Total Debt: $8.96B
Free Cash Flow: $-1.20B
Revenue Growth: 16.50%
Earnings Growth: -46.30%
Enterprise Value: $38.56B

RPRX Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$2.24B	$2.35B	$2.26B	$2.38B
Research & Development	$177.11M	$52.00M	$2.00M	$452.00M
Selling, General & Admin	$227.30M	$249.75M	$236.67M	$573.48M
Operating Expenses	$1.31B	$862.40M	$971.13M	$818.67M
Operating Income	$922.89M	$1.49B	$1.29B	$1.56B
EBITDA	$423.69M	$1.89B	$1.56B	$1.64B
Pretax Income	$230.06M	$1.70B	$1.33B	$1.32B
Income Tax	$0.00	$0.00	$0.00	$0.00
Net Income	$42.83M	$1.13B	$858.98M	$770.95M
Diluted EPS	0.10	2.53	1.45	1.37
Diluted Shares	437.97M	602.90M	594.00M	564.00M

RPRX Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$1.71B	$477.01M	$929.03M	$618.70M
Receivables	$36.60M	$22.41M	$26.96M	$29.32M
Current Assets	$2.55B	$1.27B	$1.80B	$1.53B
Total Assets	$16.81B	$16.38B	$18.22B	$19.62B
Current Liabilities	$1.17B	$161.38M	$1.25B	$636.21M
Long-Term Debt	$6.12B	$6.14B	$6.61B	$8.57B
Total Debt	$7.12B	$6.14B	$7.61B	$8.95B
Total Liabilities	$7.29B	$6.30B	$7.88B	$9.91B
Retained Earnings	$1.96B	$2.52B	$2.85B	$2.36B
Shareholders' Equity	$5.63B	$6.53B	$6.95B	$6.48B
Working Capital	$1.39B	$1.11B	$548.52M	$891.88M
Net Debt	$5.41B	$5.66B	$6.68B	$8.33B

RPRX Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	$2.14B	$2.99B	$2.77B	$2.49B
Free Cash Flow	$2.14B	$2.99B	$2.77B	$2.49B
Depreciation & Amortisation	$5.67M	$0.00	$0.00	$3.85M
Stock-Based Compensation	$2.17M	$2.36M	$2.34M	$289.89M
Investing Cash Flow	-$1.03B	-$2.07B	-$2.68B	-$1.61B
Financing Cash Flow	-$944.86M	-$2.15B	$361.14M	-$1.19B
Dividends Paid	-$333.32M	-$358.33M	-$376.46M	-$378.25M
Share Repurchases	$0.00	-$304.76M	-$229.65M	-$1.23B
Net Change in Cash	$169.70M	-$1.23B	$452.02M	-$310.33M

RPRX Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$568.25M	$578.66M	$609.29M	$621.99M	$630.58M
Research & Development	$50.50M	$300.50M	$50.50M	$50.50M	$39.79M
Selling, General & Admin	$110.70M	$179.77M	$118.73M	$164.27M	$159.49M
Operating Expenses	$34.06M	$368.87M	$182.13M	$233.61M	-$1.91M
Operating Income	$534.18M	$209.80M	$427.16M	$388.38M	$632.48M
EBITDA	$499.69M	$160.68M	$525.05M	$451.28M	$563.15M
Pretax Income	$434.43M	$90.64M	$444.21M	$355.91M	$468.26M
Income Tax	$0.00	$0.00	$0.00	$0.00	$0.00
Net Income	$239.35M	$30.18M	$288.22M	$214.21M	$294.69M
Diluted EPS	0.41	0.05	0.51	0.38	0.53
Diluted Shares	578.00M	562.00M	560.00M	556.00M	557.00M

RPRX Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$1.09B	$631.91M	$938.94M	$618.70M	$586.39M
Receivables	$23.79M	$27.74M	$28.90M	$29.32M	$27.51M
Current Assets	$1.84B	$1.52B	$1.85B	$1.53B	$1.43B
Total Assets	$17.61B	$18.32B	$19.35B	$19.62B	$19.82B
Current Liabilities	$1.18B	$1.21B	$530.80M	$636.21M	$535.68M
Long-Term Debt	$6.62B	$7.00B	$8.57B	$8.57B	$8.58B
Total Debt	$7.62B	$8.00B	$8.95B	$8.95B	$8.96B
Total Liabilities	$7.82B	$8.82B	$9.73B	$9.91B	$9.88B
Retained Earnings	$2.48B	$2.22B	$2.30B	$2.36B	$2.51B
Shareholders' Equity	$6.69B	$6.35B	$6.41B	$6.48B	$6.89B
Working Capital	$660.39M	$313.71M	$1.32B	$891.88M	$890.13M
Net Debt	$6.53B	$7.37B	$8.01B	$8.33B	$8.37B

RPRX Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	$596.08M	$363.98M	$702.62M	$827.15M	$718.23M
Free Cash Flow	$596.08M	$363.98M	$702.62M	$827.15M	$718.23M
Depreciation & Amortisation	$0.00	$1.38M	$1.28M	$1.20M	$1.17M
Stock-Based Compensation	$515.00K	$90.77M	$72.84M	$125.77M	$121.99M
Investing Cash Flow	$503.92M	-$311.98M	-$958.31M	-$847.80M	-$477.87M
Financing Cash Flow	-$941.30M	-$507.81M	$562.74M	-$299.60M	-$272.67M
Dividends Paid	-$95.36M	-$93.24M	-$95.31M	-$94.34M	-$104.49M
Share Repurchases	-$708.78M	-$291.57M	-$146.49M	-$80.54M	-$50.10M
Net Change in Cash	$158.69M	-$455.81M	$307.04M	-$320.25M	-$32.30M

Market Snapshot

About

Royalty Pharma is the largest buyer of biopharmaceutical royalties, owning royalty interests in dozens of commercial and development-stage products. The company acquires royalty streams from pharmaceutical companies and academic institutions, providing upfront capital in exchange for future revenue shares. Royalty Pharma's portfolio includes treatments across therapeutic areas including immunology, infectious disease, oncology, and rare diseases. The firm operates a diversified revenue model based on the commercial success of approved therapies.